All In Biotech

Drug Trial Radar · NCT04580420

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Apr 15, 2021

Primary completion

Dec 30, 2031

Study completion Jan 30, 2032

Sponsor

Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Conditions

  • Primary Hyperoxaluria Type 1
  • End Stage Renal Disease

Interventions

  • DCR-PHXCDrug

    Monthly dosing throughout study period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of EventsTime frame: 180 days
  2. Safety: Incidence of EventsTime frame: 180 days

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    San Francisco, California · Active not recruiting

  • Clinical Trial Site

    Boston, Massachusetts · Active not recruiting

  • Clinical Trial Site

    Rochester, Minnesota · Recruiting

  • Clinical Trial Site

    New York, New York · Active not recruiting

  • Clinical Trial Site

    Bron, France · Withdrawn

  • Clinical Trial Site

    Paris, France · Withdrawn

  • Clinical Trial Site

    Bonn, Germany · Recruiting

  • Clinical Trial Site

    Heidelberg, Germany · Withdrawn

  • Clinical Trial Site

    Roma, Italy · Withdrawn

  • Clinical Trial Site

    Beirut, Lebanon · Recruiting

  • Clinical Trial Site

    Casablanca, Morocco · Withdrawn

  • Clinical Trial Site

    Oradea, Romania · Withdrawn

  • Clinical Trial Site

    Oradea, Romania · Withdrawn

  • Clinical Trial Site

    Barcelona, Spain · Recruiting

  • Clinical Trial Site

    Santa Cruz de Tenerife, Spain · Withdrawn

  • Clinical Trial Site

    Dubai, United Arab Emirates · Recruiting

  • Clinical Trial Site

    London, United Kingdom · Withdrawn

  • Clinical Trial Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.